The European Medicines Agency has set up R&D support, business support, inspections and evaluation divisions under a restructuring plan intended to improve how it shares information and supports its scientists. The agency said the changes are part of a 2014 restructuring that will benefit drugmakers and patients and change the way it carries out reviews and inspections.

Related Summaries